

## Malawi Support for Measles-Rubella Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Malawi					
<b>2. Grant number:</b> 1820-MWI-09a-X / 15-MWI-08d-Y /					
<b>3. Date of Decision Letter:</b> 23 March 2018					
<b>4. Date of the Partnership Framework Agreement:</b> 22 October 2014					
<b>5. Programme title:</b> New vaccine support (NVS), Measles-Rubella Second dose through Measles Second Dose Routine					
<b>6. Vaccine type:</b> Measles-Rubella					
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED					
<b>8. Programme duration<sup>1</sup>:</b> 2015 -2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	641,839 <sup>3</sup>	224,500	241,500	245,000	1,352,839
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$558,500 was disbursed on 16/01/2015 for Measles 2 <sup>nd</sup> dose.					
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2015-2017	2018			
Number of Measles vaccine doses		801,700			
Annual Amounts (US\$)	US\$641,839 <sup>5</sup>	US\$224,500			
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>13. Self-procurement:</b> Not applicable.					
<b>14. Co-financing obligations:</b> Not applicable					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>15. Operational support for campaigns:</b> Not applicable		
<b>16. Additional reporting requirements:</b> Not applicable		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
<b>17. Financial clarifications:</b> Not applicable		
<b>18. Other conditions:</b>		
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine second dose, with country funding the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.		
	2018	
Number of doses of vaccines for Measles Second Dose approved by Gavi.	801,700	
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	216,459	
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	350,257	
Number of doses of Measles-Rubella vaccine to be funded by country.	451,443	
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	278,992	
<p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement</p>		

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
 Managing Director, Country Programmes  
 23 March 2018